IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
The over-the-counter (OTC) pain medication manufacturing has undergone significant shifts in recent years, shaped by global supply chain pressures, regulatory changes and evolving consumer behaviours. The demand for OTC pain relief saw an unprecedented spike at the onset of the COVID-19 pandemic in early 2020, as consumers scrambled to manage symptoms like fever and body aches at home, prompting temporary rationing and government-imposed sales limits. However, the subsequent pandemic restrictions, like lockdowns and social distancing, dampened demand in 2020-21 and 2021-22. Despite these fluctuations, the industry rebounded in 2022-23 during a severe flu season, revealing the extent to which public health events can drive consumer reliance on OTC remedies. Industry revenue is expected to climb at an annualised rate of 0.2% over the five years through 2025-26, reaching $890.6 million. This includes a 0.3% dip in the current year.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the OTC Pain Medication Manufacturing industry in Australia includes market sizing, forecasting, data and analysis from 2016-2031. The most recent publication was released February 2026.
The OTC Pain Medication Manufacturing industry in Australia operates under the ANZSIC industry code OD5247. Industry companies develop and manufacture over-the-counter (OTC) pain-relief medication. Products manufactured by the industry are available without a prescription from pharmacy and grocery shops. Prescription narcotic and opioid analgesics are not included in the industry. Related terms covered in the OTC Pain Medication Manufacturing industry in Australia include nsaids, pbs, general sales medicines (gsm), scheduling of medicines, schedule 2 pharmacy medicines, schedule 3 pharmacist-only medicines and schedule 4 prescription-only medicines .
Products and services covered in OTC Pain Medication Manufacturing industry in Australia include Acetaminophens, Propionic acid derivatives of NSAIDs and Other NSAIDs.
Companies covered in the OTC Pain Medication Manufacturing industry in Australia include DBG Consolidated Holdings Pty Ltd, Aspen Pharma and Evaris Pharma.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the OTC Pain Medication Manufacturing industry in Australia.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed product and service segmentation, analysis of major markets and international trade data for the for the OTC Pain Medication Manufacturing industry in Australia.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the OTC Pain Medication Manufacturing industry in Australia.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the OTC Pain Medication Manufacturing industry in Australia. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the OTC Pain Medication Manufacturing industry in Australia. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the OTC Pain Medication Manufacturing industry in Australia. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the OTC Pain Medication Manufacturing industry in Australia. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the OTC Pain Medication Manufacturing industry in Australia.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the OTC Pain Medication Manufacturing industry in Australia is $890.6m in 2026.
There are 23 businesses in the OTC Pain Medication Manufacturing industry in Australia, which has declined at a CAGR of 0.8 % between 2021 and 2026.
The OTC Pain Medication Manufacturing industry in Australia is likely to be significantly impacted by import tariffs with imports accounting for a high share of industry revenue.
The OTC Pain Medication Manufacturing industry in Australia is likely to be impacted by export tariffs with exports accounting for a moderate share of industry revenue.
The market size of the OTC Pain Medication Manufacturing industry in Australia has been growing at a CAGR of 0.2 % between 2021 and 2026.
Over the next five years, the OTC Pain Medication Manufacturing industry in Australia is expected to grow.
The biggest companies operating in the OTC Pain Medication Manufacturing industry in Australia are DBG Consolidated Holdings Pty Ltd, Aspen Pharma and Evaris Pharma
Acetaminophens and Propionic acid derivatives of NSAIDs are part of the OTC Pain Medication Manufacturing industry in Australia.
The company holding the most market share in the OTC Pain Medication Manufacturing industry in Australia is DBG Consolidated Holdings Pty Ltd.
The level of competition is moderate and increasing in the OTC Pain Medication Manufacturing industry in Australia.